Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
Healthcare | Drug Manufacturers - Major | USA
financial highlights | statements
IndexS&P 500 P/E23.14 EPS (ttm)2.74 Insider Own0.10% Shs Outstand1.65B Perf Week1.62%
Market Cap104.47B Forward P/E20.00 EPS next Y3.18 Insider Trans-4.88% Shs Float1.64B Perf Month12.09%
Income4.59B PEG2.55 EPS next Q0.76 Inst Own70.30% Short Float0.62% Perf Quarter13.23%
Sales20.24B P/S5.16 EPS this Y184.60% Inst Trans-1.78% Short Ratio1.54 Perf Half Y12.65%
Book/sh8.94 P/B7.10 EPS next Y6.62% ROA13.70% Target Price58.00 Perf Year14.27%
Cash/sh3.95 P/C16.06 EPS next 5Y9.07% ROE30.10% 52W Range46.01 - 63.47 Perf YTD8.64%
Dividend1.56 P/FCF72.05 EPS past 5Y4.20% ROI19.80% 52W High0.03% Beta1.18
Dividend %2.46% Quick Ratio1.50 Sales past 5Y-1.80% Gross Margin73.50% 52W Low37.99% ATR0.92
Employees25000 Current Ratio1.60 Sales Q/Q5.60% Oper. Margin29.50% RSI (14)73.96 Volatility1.39% 1.52%
OptionableYes Debt/Eq0.56 EPS Q/Q-20.10% Profit Margin22.70% Rel Volume0.84 Prev Close62.93
ShortableYes LT Debt/Eq0.47 EarningsOct 26 BMO Payout55.80% Avg Volume6.56M Price63.49
Recom2.50 SMA204.64% SMA509.74% SMA20013.81% Volume5,561,290 Change0.89%
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Sep-20-17 03:50PM  2 Important Dates for Big Pharma GuruFocus.com
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-18-17 10:19AM  Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear InvestorPlace
09:42AM  The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 Motley Fool
Sep-17-17 07:03AM  Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb Motley Fool
07:02AM  Bristol-Myers Squibb Stock Still a Beast? TheStreet.com
Sep-16-17 10:47AM  Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? Motley Fool
Sep-15-17 11:41AM  Time to Adjust as Bristol-Myers Squibb Continues Its Climb TheStreet.com
10:55AM  Oncology Space in Focus this Week on ESMO Presentations Zacks
09:34AM  Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE Zacks
06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
06:04AM  Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis? Motley Fool
Sep-14-17 04:20PM  This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche Investor's Business Daily
03:43PM  Halozyme to license drug delivery tech to Bristol-Myers a... CNBC Videos
03:19PM  Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale Motley Fool
11:45AM  Here's Why Halozyme Therapeutics, Inc. Is Soaring Today Motley Fool
08:00AM  Halozyme to license drug delivery tech to Roche, Bristol-Myers Reuters
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
08:00AM  Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take Forbes
07:18AM  Halozyme's stock soars after Bristol-Myers license deal MarketWatch
07:00AM  Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers TheStreet.com
06:59AM  Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology Business Wire
Sep-13-17 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
04:15PM  Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors Business Wire
01:35PM  [$$] Bristol-Myers Stock May Be Fully Valued Barrons.com
Sep-12-17 05:36PM  Bristol-Myers Reports Positive Results from Melanoma Study Zacks
10:17AM  Company News For Sep 12, 2017 Zacks
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-11-17 10:05AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
05:32AM  Cancer immunotherapy proves itself in earlier-stage disease Reuters
Sep-10-17 06:11PM  Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study Business Wire
06:05PM  After melanoma surgery, Bristol's Opdivo offers new care standard Reuters
01:00PM  Bristol's drug cocktail cuts kidney cancer death risk 37 pct Reuters
11:55AM  Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial Business Wire
11:55AM  Bristol kidney cancer drug cut death risk 37 pct in key patients Reuters
Sep-08-17 03:22PM  Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer Investor's Business Daily
10:34AM  2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August Motley Fool
10:21AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
09:45AM  Bristol-Myers' Opdivo Study Meets Early Success, Stock Up Zacks
08:20AM  Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold Zacks
06:08AM  Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock Motley Fool
05:30AM  Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Business Wire
03:00AM  Stocks Flashing Renewed Technical Strength: Bristol-Myers Squibb Investor's Business Daily
Sep-07-17 06:10PM  3 Stocks Soaring Today GuruFocus.com
04:30PM  Bristol-Myers Squibb Completes Previously Announced Acquisition of IFM Therapeutics Business Wire
02:00PM  Bristol-Myers Squibb: And Just Like That Barrons.com
01:07PM  FDA widens holds on immunotherapy combination blood cancer trials Reuters
08:58AM  Bristol-Myers kidney cancer drug meets early success, study stopped Reuters
07:23AM  Bristol-Myers Squibb says late-stage cancer drug combination study met endpoints and will be stopped early MarketWatch
07:22AM  Bristol-Myers kidney cancer drug meets main goal of late-stage trial Reuters
06:59AM  CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
06:59AM  Bristol-Myers Squibb to Announce Results for Third Quarter 2017 on October 26 Business Wire
Sep-06-17 06:17PM  Bristol-Myers says FDA places partial hold on Opdivo myeloma trials Reuters
09:57AM  Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln Reuters
07:00AM  Bristol-Myers Squibb Employees Ride Across the U.S. to Raise Money to Support Cancer Research by Stand Up To Cancer Business Wire
03:00AM  IBD Rating Upgrades: Bristol-Myers Squibb Flashes Improved Relative Price Strength Investor's Business Daily
Sep-05-17 06:59AM  Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference Business Wire
Sep-04-17 08:05AM  Key FDA Regulatory Events to Watch Out for in Sep 2017 Zacks
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-02-17 08:06AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-01-17 05:32PM  Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda Zacks
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Aug-31-17 03:02PM  Eli Lillys Valuations after Its 2Q17 Earnings Market Realist
09:28AM  Bristol-Myers Squibb Is Primed for an Upside Breakout TheStreet.com
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:36AM  Bristol-Myers Squibbs Immunoscience Products in 2Q17 Market Realist
Aug-30-17 06:05PM  Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Companys Innovative Research Approach to Treating Cancer from All Angles Business Wire
11:46AM  Merck: Heartbreak Over A Cholesterol Drug Barrons.com
10:37AM  Performance of Bristol-Myers Squibbs Eliquis in 2Q17 Market Realist
09:08AM  Bristol-Myers Squibbs Virology Products in 2Q17 Market Realist
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:37AM  Performance of Bristol-Myers Squibbs Opdivo in 2Q17 Market Realist
Aug-29-17 04:35PM  Bristol-Myers Squibbs Oncology Products in 2Q17 Market Realist
03:05PM  Bristol-Myers Squibbs Revenues in 2Q17 Market Realist
01:12PM  Bristol-Myers Squibbs Valuation after 2Q17 Earnings Market Realist
11:45AM  Pfizer Presents Encouraging Eliquis Results in NVAF Patients Zacks
08:21AM  Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation Business Wire
Aug-28-17 05:06PM  Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers Reuters
04:40PM  Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers Reuters
04:01PM  Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers Business Wire
02:59PM  A Look at Johnson & Johnsons Post-2Q17 Valuation Market Realist
05:00AM  Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion Business Wire
02:30AM  Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation Business Wire
Aug-27-17 03:04PM  Can Buying Exelixis Stock Still Make You Rich? Motley Fool
Aug-24-17 05:42PM  Celldex Ends Phase II Enrollment for Breast Cancer Candidate Zacks
Aug-23-17 11:53AM  Incyte Had These Key Collaborations and Developments in 2Q17 Market Realist
Aug-22-17 03:47PM  What's Next for Bristol-Myers Squibb After Its Opdivo Setback? Motley Fool
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:36AM  Eliquis and Sprycel Could Boost BMYs Revenue Growth in 2H17 Market Realist
Aug-21-17 02:25PM  Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : July 07th, 2017 (record date) : By the numbers : August 21, 2017 Capital Cube
10:36AM  Orencia Could Witness Robust Growth in 2017 Market Realist
09:06AM  Bristol-Myers Squibbs Yervoy Is Expected to See Steady Growth Market Realist
07:36AM  Bristol-Myers Squibbs Opdivo Could Be a Long-Term Growth Driver Market Realist
Aug-18-17 10:38AM  Opdivo Could Drive Bristol-Myers Squibbs Revenue Growth in 2017 Market Realist
09:08AM  Chart in Focus: Bristol-Myers Squibbs Performance in 2Q17 Market Realist
07:39AM  Analysts Recommendations for Bristol-Myers Squibb in August 2017 Market Realist
07:09AM  Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo Zacks
06:59AM  Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017 Business Wire
Aug-17-17 05:59PM  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx Zacks
Aug-16-17 03:31PM  [$$] Bristol-Myers Can Overcome Market's Pessimism Barrons.com
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
open in yahoo | open in reuters | open in google